WCBA
FPRX

Weaver C. Barksdale & Associates’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-56
Closed -$2K – 506
2017
Q2 		$2K Hold
56
– – ﹤0.01% 485
2017
Q1 		$2K Hold
56
– – ﹤0.01% 485
2016
Q4 		$3K Hold
56
– – ﹤0.01% 463
2016
Q3 		$3K Buy
+56
New +$2.67K 0.01% 453

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Weaver C. Barksdale & Associates's FPRX Position: Q3 2017 in Review

Weaver C. Barksdale & Associates sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2017, closing a stake of 56 shares — an estimated $2K sold.

Weaver C. Barksdale & Associates first reported a position in FPRX in Q3 2016 and held it in 4 quarters. The position peaked at $3K in Q4 2016. 126 funds tracked by Wall St. Rank hold FPRX as of Q3 2017.

  • Weaver C. Barksdale & Associates reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Weaver C. Barksdale & Associates sold 56 Five Prime Therapeutics, Inc. shares in Q3 2017, an estimated $2K.
  • Weaver C. Barksdale & Associates first reported a position in Five Prime Therapeutics, Inc. in Q3 2016 and held it in 4 quarters.
  • Weaver C. Barksdale & Associates's Five Prime Therapeutics, Inc. position peaked at $3K in Q4 2016.
  • 126 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2017.

Based on Weaver C. Barksdale & Associates's 13F filing for Q3 2017, filed 12 Oct 2017.